Immunological enhancement: a study of blocking antibodies

Redox-reactive autoantibodies: Detection and physiological relevance

We recently described a hitherto unrecognized family of autoantibodies that become unmasked (detectable) subsequent to oxidation-reduction (redox) reactions. These masked redox-reactive autoantibodies are not detectable by using conventional immunoassays. Additional experimentation has demonstrated that autoantibodies in the blood of patients with autoimmune diseases can be masked (become undetectable) by exposure to oxidizing agents. Simultaneous masking and unmasking of different autoantibodies in a given patient's serum or plasma is evidence that immune complexes are not the source of redox-reactive autoantibodies. We propose that a mechanism responsible for unmasking-masking antibody specificities requires nitrosylation of tyrosine residues in the hypervariable or complementarity determining regions of the antibodies' antigen-binding sites. Other laboratories, selected by us for their respective expertise, have studied our redox-reacted and control serum and/or antibody preparations and have found an expanding array of autoantibody specificities. The gathering data suggest that certain autoimmune diseases may involve redox disorders rather than a failure to deplete, suppress, tolerate or divert self-directed B cell activity. The persistence and fluctuation of redox-reactive autoantibodies suggest that they are manifestations of an as yet undefined natural selective pressure on the evolution of the immunological system. We propose that they are the "contrivances" suggested by Paul Ehrlich more than a hundred years ago, and that these antibodies perform important physiological and pathophysiological functions.

Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2

A plasmid DNA was constructed to encode the N-terminal 505 aa of human ErbB-2 (E2, HER-2/neu) and designated as secreted ErbB-2 (secE2). Recombinant secE2 protein was detected in the transfected cells and was secreted as an 80-kDa glycoprotein. Vaccination of BALB/c mice with secE2 DNA induced both IgG1 and IgG2a ErbB-2-specific Abs and protected approximately 90% of mice against mouse mammary tumor D2F2, which expressed human ErbB-2 (D2F2/E2). The efficacy of secE2 vaccine was comparable with that of wild-type ErbB-2 DNA, which encodes the entire 1258 aa of ErbB-2 protein, induced only IgG2a E2-specific Abs, and stimulated greater CTL activity. Immune lymphocytes were stimulated in vitro with irradiated 3T3 cells, which expressed ErbB-2, K(d), and B7.1. CTL activity was measured by the lysis of E2-positive target cells and by intracellular IFN-gamma production. To enhance CTL activation, mice were immunized with a combination of secE2 and cytoplasmic E2 (cytE2); the latter encodes the 1258-aa ErbB-2 protein that was released into the cytoplasm upon synthesis. Significant increase in CTL activity was demonstrated after mice were immunized with the combined vaccines and all mice were protected from D2F2/E2 tumor growth. Therefore, secE2, which induced Th2 Ab and weak CTL, conferred similar protection as E2, which induced Th1 Ab and strong CTL. Combined vaccination with secE2 and cytE2 resulted in Th2 Ab, strong CTL, and the most effective protection against tumor growth. The strategy of coimmunization with DNA that direct Ags to different subcellular compartments may be adapted as appropriate to optimize immune outcome.

Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

Wild-type ErbB-2 (E2) positive D2F2/E2 tumors are rejected by active vaccination with ErbB-2 DNA. However, anti-ErbB-2 Ab response can cause cardiac toxicity or interfere with cellular immunity. It will be advantageous to induce only cellular immunity by active vaccination. A panel of E2 DNA vaccines were constructed, and their vaccination efficacy was ranked as E2 > tyrosine kinase-deficient ErbB-2 (E2A) > full-length ErbB-2 targeted to the cytoplasm (cytE2) > tyrosine kinase-deficient cytE2 (cytE2A). E2A is a tyrosine kinase-deficient mutant containing a single residue substitution. CytE2 or cytE2A encodes a full-length protein that is targeted to and rapidly degraded in the cytosol by the proteasomes. Covaccination with cytE2A and GM-CSF or IL-2 DNA resulted in equivalent anti-tumor activity as E2. However, anti-ErbB-2 Ab was induced by E2 or E2A, but not cytE2 or cytE2A. Therefore, cytE2A appears to induce anti-tumor immunity without an Ab response. ErbB-2-specific CTL were detected in mice immunized with cytE2A and GM-CSF and have rejected tumor challenge. Depletion of CD8, but not CD4 T cells reduced anti-tumor immunity, indicating CTL as the effector cells. Covaccination with E2A and cytE2A induced synergistic anti-tumor activity, supporting enhanced peptide presentation from cytE2A, which was further evidenced by superior CTL activation using APCs expressing cytE2 vs E2. Taken together, cytoplasmic ErbB-2 DNA induced anti-tumor CTL, but not humoral response, demonstrating the feasibility of eliciting individual effector mechanism by targeted DNA vaccine.

Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies

We investigated the potential role of anti-tumor antibodies and tumor antigens in the formation of immune complexes which promote matrix degradation and angiogenesis. B-cell deficient or B-cell depleted mice showed a reduction in tumor invasion and metastasis. In vitro invasion assays and in vivo models of metastasis showed that anti-sTn antibodies and sTn tumor antigens form complexes which induce granulocytes and macrophages together to mediate tumor invasion and metastasis by processes including extracellular matrix degradation and angiogenesis. These results suggest the existence of a tumor promoting role of a B-cell immune response induced by shed tumor associated antigens of solid, nonlymphoid tumors.

B cells inhibit induction of T cell-dependent tumor immunity

Cytotoxic T lymphocyte (CTL) mediated tumor immunity against major histocompatibility antigen (MHC) class I-positive but class II-negative tumors often requires help from CD4+ T cells. These CD4 cells are activated by MHC class II-positive cells that present tumor derived antigens. Considering that different antigen presenting cells, such as B cells, macrophages and dendritic cells compete for antigen and influence the outcome of an immune response, we analyzed tumor immunity in B cell-deficient mice. These mice appear normal with regard to T cell immunity and tolerance to some pure foreign antigens. We show here that the low immunogenicity of tumors is caused by B cells whose presence in the priming phase results in disabled CD4+ T cell help for CTL mediated tumor immunity. Instead, in the presence of B cells, a non-protective humoral immune response is induced. Our results may explain the enigmatic observation that tumor-reactive antibodies occur frequently in cancer patients.

Fetal-maternal immune interaction: blocking antibody and survival of the fetus

In the late 1940s it became clear that the homograft reaction was essentially the result of an immune response. Subsequently, Medawar commented on the apparent paradox of the survival of the mammalian fetus in the face of such a potential (cell-mediated) immune response. In an outbred population the fetal-placental unit will be antigenically different to the mother by virtue of its complement of paternal genes and additionally there may be developmental or stage-specific gene products that are immunogenic. Many mechanisms have been proposed to account for the survival of the fetus in the face of a potential immune attack and, while many of these have been investigated in considerable detail, there has been no clear-cut indication that any one plays a predominant role. Either control of immune rejection of the fetus is exercised by an as yet undiscovered mechanism or, more probably, by a combination of some or all of the mechanisms that have been proposed by many workers over the last three decades. Potential controlling processes, which will be reviewed briefly, include: systemic and local modification of maternal responsiveness; altered expression of MHC antigens on extra-embryonic tissues; the placenta as a barrier; and blocking antibody responses. We discuss some of our recent studies in which we have started to look for potential blocking antibodies in a mouse model system. Cells secreting immunoglobulins M and G, characterized in hemolytic plaque assays, have been mapped to areas close to the midgestation mouse embryo, using an immunocryohistological technique. A scaled-down version of hybridoma technology has been used as an analytical probe of the specificity and isotype of immunoglobulin secreted by cells originating either from close to the embryo/fetus or from the para-aortic lymph nodes (PALN). So far monoclonal (IgG1) antibodies with specificity for embryonic cells have been derived together with some monoclonal immunoglobulins with as yet uncharacterized antibody specificity.

Does antibody-dependent epitope masking permit progressive tumour growth in the face of cell-mediated cytotoxicity?

It is not clear how immunogenic tumours can grow from small inocula in syngeneic hosts that mount both T-cell and B-cell responses. In this article Lionel Manson argues that antibody coats the tumour cells, protecting them from attack by cytotoxic lymphocytes, and thus permits the tumour to continue to grow and overwhelm the host. These observations may explain the paradox that an immunogenic tumour overwhelms the tumour-bearing host in the face of an ongoing anti-tumour immune response.

Immunohistochemical evidence of immune responses to tumor-associated antigens in lymph nodes of colon carcinoma patients

The authors investigated by immunohistochemical study the drainage of three tumor-associated antigens in unaffected regional lymph nodes of colon cancer patients. The study was conducted using monoclonal antibodies (MoAb) directed against different epitopes of the tumor-associated glycoprotein, TAG-72 (CC-49, CC-83, B72.3), of the carcinoembryonic antigen (CEA) (COL-4, COL-12), and of the colon-associated antigen, CAA (anti-CAA). The authors detected immunohistochemical reactions of MoAb CC-49 and anti-CAA with antigen-presenting cells (APC), such as peritumoral and sinus macrophages and lymphatic endothelial cells and with specific areas of germinal centers in lymph nodes draining 11 of 24 colorectal carcinomas studied. The corresponding primary tumors expressed the TAG-72 and CAA antigens. No immunostaining was detectable in lymph nodes using the anti-CEA MoAb, even when the primary tumors strongly expressed the specific epitopes. In germinal centers of regional lymph nodes, the immunostaining was often distributed at the periphery with a characteristic crescentic or circular pattern, which strongly suggested the exposure of the specific epitopes defined by MoAb CC-49 and anti-CAA on follicular dendritic cells. This would indicate that these epitopes are selectively recognized and presented to germinal center B-cells. This phenomenon may have clinical and diagnostic implications.

Monoclonal antibodies identify new Toxoplasma gondii soluble antigens

In order to characterize Toxoplasma gondii antigens, we have produced a panel of monoclonal antibodies specific for the parasite. A total of 22 hybridomas were derived from the spleen cells of mice immunized either with a 100,000 g supernatant of a sonicate from the RH strain (called F3), or chronically infected with the Wiktor or the 76K strain. Except for one hybridoma producing an IgM, all the hybridomas derived from mice immunized with F3 produced IgG1 antibodies while those obtained from chronically infected mice produced antibodies belonging to the IgG2b, IgG2a and IgM subclasses. Western-blot analysis showed that the panel of monoclonal antibodies defines at least 7 distinct antigens or antigen families. An antigen of apparent Mw 25 kD present exclusively in the 100,000 g supernatant of the T. gondii sonicate was recognized by the majority of monoclonal antibodies derived from mice immunized with the F3 fraction. Two other antigens of apparent Mw 27 kD and 29 kD present in the soluble and insoluble fractions of the sonicate were also identified. Monoclonal antibodies against the previously described 21 kD and 31 kD surface antigens and belonging to the IgG2a but also to the IgG1 subclasses were able to mediate lysis of the parasite in the presence of human non immune serum. The 22 monoclonal antibodies did not identify antigenic differences between the two independently isolated RH and Wiktor strains.

Shedding of plasma membrane fragments. Neoplastic and developmental importance

The phenomenon of shedding of cell surface macromolecules and their importance in the cancer process has been reviewed with particular emphasis on tumor membrane fragments. With cell activation (during growth or stimulation of normal cells), there is an increase in synthesis, processing, insertion, and eventual, intact release of certain membrane proteins, some of which are proteases. In cancer, these events occur spontaneously and without the temporal, physiological, or hormonal control apparent in normal cells. In a previous review (Black, 1980), many of the consequences of shedding tumor products were described, but the nature of the shed material was not clear. It now seems likely that some proteolytic, procoagulant, and immunosuppressive activities of shed material are contained within membrane particulate material (vesicles). Under normal conditions, shed membrane material (particularly proteolytic activity) may be necessary for cell movement and tissue remodeling which occur during embryogenesis. In cancer, shedding of plasma membrane fragments may be responsible for the key features of the malignant phenotype by the presence and release of proteolytic activity producing the separation of tumor cells from the primary site, invasion of the surrounding tissues by tumor cells, and formation of distinct metastases. Shed plasma membrane fragments may play a central role in tumor progression by enhancing the steps of the metastatic cascade, in particular by increasing tumor embolus formation (by enhanced fibrin deposition and platelet aggregation) and vascular permeability, as well as increasing basement membrane degradation. Shed membrane fragments (containing tumor antigens) either alone or complexed with antibody, may be responsible for blocking the cell-mediated immune reaction by the formation of "blocking factors" or by suppressing the formation of cytotoxic immune pathways. The suppression of immune response formation may be due to blocking of antigen presentation by macrophages (due to inhibition of Ia) or by the induction of Ts1 cells.

Antibodies against a tumour-associated antigen in an AKR lymphoma conditioned to grow in BALB/c mice

An experimental model was used in which AKR lymphoma cells (L15) were conditioned to grow in BALB/c mice leading to tumour-bearing (progressor) and tumour-rejecting (regressor) animals. The behaviour of antibodies present in the sera of these animals was studied using as antigen L15 cells or a soluble tumour-associated antigen TEs. Both sera showed similar IIF and haemagglutinating activity. However differences were observed for the complement cytotoxicity assay. Regressor serum as well as a rabbit anti-tumour-associated antigen serum were strongly cytotoxic for the AKR lymphoma cells while progressor serum showed markedly lower activity. Specific antibodies against the tumour-associated antigen were purified. In both sera they were located mainly in IgG1 but also in IgG2. The purified antibodies agglutinated specifically sensitized sheep erythrocytes and reacted by indirect immunofluorescence with L15 cells but not with AKR thymocytes. It is suggested that two qualitatively different humoral immune responses are involved in the mechanisms leading to tumour enhancement or rejection.

Studies on the level of natural antibodies reactive with various tumor cells during urethane carcinogenesis in BALB/c mice

Serum from young normal BALB/c mice was found to contain IgM antibodies able to mediate complement-dependent lysis of certain syngeneic or allogeneic tumor target cells. The titer of such naturally occurring antitumor antibodies ( NATA ) was found to increase with aging. A longitudinal serological study comparing the cytotoxicity potential of NATA from normal and from urethan-treated BALB/c mice was performed. It was found that urethan-treated mice that did not develop primary lung-adenomas within the duration of the experiment had significantly lower NATA titers, against one out of 4 target cells assayed, than urethan-treated animals that developed lung adenomas. This difference was evident in two independent experiments. The results suggested that the lower NATA activity of the urethan-treated mice that did not develop tumors existed even before exposure to the carcinogenic insult. This raises the possibility that certain populations could be segregated according to their natural antibody profile into those individuals which will develop primary tumors within a certain period if exposed to a subthreshold amount of carcinogen, and those which will not.

Immunological regulation of Angiostrongylus cantonensis infections in rats: modulation of population density and enhanced parasite growth following one or two superimposed infections

Rats acquired a degree of protective immunity to reinfection with Angiostrongylus cantonensis after a single infection with 50 infective larvae. Infected rats resisted the establishment of most challenging larvae and protective immunity increased with subsequent reinfections. Part of the primary infection was lost after a superimposed second and also following a superimposed third infection, but the total size of the concurrent adult worm populations remained the same as that from a primary infection. Worms surviving from the primary infection showed enhanced growth after each reinfection but their fecundity was impaired.

"Membrane-associated" immunoglobulins in cyst and ascites fluids of ovarian cancer patients

A new column chromatography technique, utilizing peroxidase-labeled antihuman immunoglobulins, is described, which can measure the binding of specific antibodies to membrane fragments containing relevant antigens. Using this assay, the presence of bound immunoglobulin is demonstrated on membrane fragments isolated from ascites fluids, but not from tumor tissues. In this study, two populations of immunoglobulins were examined: 'free' immunoglobulins and immunoglobulins bound to ascites fluid-derived membrane fragments. Immunoglobulins eluted from membrane fragments of the ascites fluids were capable of binding to the tumor. These were specific for binding to tumor membrane preparations, in that there was two orders of magnitude greater binding of these immunoglobulins at a given concentration than 'free' immunoglobulins at the same concentration.

Selective depletion of NK cell activity in vivo and its effect on the growth of NK-sensitive and NK-resistant tumor cell variants

Intravenous injection of rabbit anti-asialo-GM1 serum, an antiserum previouslY shown to eliminate splenic natural killer (NK) activity in vitro, profoundly depressed NK activity in CBA, DBA/2 and BALB/c nu/nu mice. The effect on NK activity was selective, as treatment of mice with anti-asialo-GM1 serum did not affect the development of other cytotoxic cells including cytotoxic macrophages following injection of poly I:C, or cytotoxic T cells in response to allogeneic cells. The role of NK cells in controlling tumor cell growth was investigated using an NK-sensitive (cl 27v-1C2) and an NK-resistant (cl 27av) subline of the murine lymphoma L5178Y. Initial studies showed that cl 27v-1C2 cells were at least 100 times less tumorigenic than were cl 27av cells in both syngeneic DBA/2 mice and BALB/c nu/nu mice. In addition, treatment of DBA/2 mice with poly I:C, which boosted NK activity, markedly depressed the growth of cl 27v-1C2 cells, but not of cl 27av cells. On the other hand, treatment of DBA/2 mice and BALB/c nu/nu mice with anti-asialo-GM1 serum led to a marked increase in tumorigenicity of cl 27v 1C2 cells, but had no effect on the tumorigenicity of cl 27av cells. In addition, the protection against cl 27v-1C2 growth afforded by poly-I:C treatment was abrogated by injection oif anti-asialo-GM1 serum. The possibility that the effects observed were caused by binding of the injected antibodies to the tumor cells was minimized by: (1) using a clone of tumor cells (cl 27v-1C2) that lacks chemically detectable asialo-GM1, and (2) pretreating animals with anti-asialo-GM1 rather than administering antiserum and tumor cells concurrently. These studies provided compelling evidence that NK cells could play an active role in controlling tumor growth. Selective depletion of NK activity by injection of anti-asialo-GM1 serum is a method which would be generally applicable to studying the role of NK cells in disease processes.

Escape of tumours from immunological destruction

This paper reviews the mechanisms of tumour escape from immune destruction that have been delineated in the past 2 decades. Current evidence indicates that the principal escape mechanisms are (i) weak or absent immunogenicity (ii) immunosuppression by tumour antigens or antigen-antibody complexes (iii) induction of suppressor cells and (iv) production of immunosuppressive factors. A classification of tumour escape mechanisms is presented.

Complement fixation by IgM and IgG autoantibodies on cultured human glial cells

The humoral immune response to autologous gliomas has been investigated in 16 patients using immune adherence and anti-C3 immunofluorescence assays of serum samples. Significant antiglioma antibody activity was detected in 56% of these sera. Fractionation experiments demonstrated that IgM class antibodies were more effective that IgG in their ability to fix complement on cultured glioma cell membranes. In addition, autologous IgG was shown to inhibit IgM complement-fixing activity in some experiments. "Capping" of immune complexes on the glioma cell surface is also described.

The brain and subarachnoid space as possible sites for endocrine tissue transplantation

Immunological rejection has been the major problem limiting the successful transplantation of tissue from one animal to another. Recent technological developments, combined with the use of the central nervous system as an immunologically privileged site, suggest that it might be possible to achieve long-term survival of hormone-secreting tissues, between two gentically dissimilar animals, if these tissues are transplanted to the brain and subarachnoid space of the host. The physiological parameters that should be considered in the clinical application of a transplant of this type are discussed.

Antibody responses to toxoplasma antigens in mice infected with strains of different virulence

Swiss Webster mice were infected with either the relatively virulent C56 strain or the relatively avirulent C37 strain of Toxoplasma gondii, and the sequence of their antibody response to surface antigens of the parasite was studied. An immunoglobulin M (IgM) agglutinating antibody was the first serologically detectable antibody and was first detected on day 2 in mice infected with the C37 strain and on day 5 in mice infected with the C56 strain. IgG antibodies were first detected on day 8 for both strains. The major component of the IgG antibodies was IgG2:IgG3 antibodies had lower titers, and no IgG1 antibodies were detected. The IgG antibodies were active in direct parasite agglutination and in the complement-dependent cytotoxicity assay of Sabin and Feldman (Science 108:660-663, 1948). On sodium dodecyl sulfate-polyacrylamide gel electrophoresis, sera from mice infected with T. gondii detected all major radioiodinated surface proteins of toxoplasma tachyzoites. The earliest time point at which these antigens were detected differed for the two strains. Serum from mice infected with C56 strain immunoprecipitated all cell surface antigens by day 10 of infection, whereas serum from mice infected with the C37 strain did not do so until day 15 of infection.

Immunological enhancement induced by gastrointestinal immunization of mice pretreated with cyclophosphamide

The present study suggests that pretreatment of mice with cyclophosphamide (CPA) not only suppresses the intestinal immune response to malignant ascites cells but alters the character of the response. Non-treated animals were sensitized by intestinal immunization while CPA-treated animals showed enhanced tumour growth. Sera from enhanced mice contained factors which at the tumor cell membrane were able to interfere with the binding of antibodies detectable by immunofluorescence technique. These factors might be immunoglobins with similarities to IgG, but bound to antigen they were undetectable by the fluorescence method. Enhanced mice were found to be immunologically hyporesponsive to the challenging tumor graft as evidenced by a delay in the immune response to the graft.

Pathogenesis and host response in subcutaneous alveolar hydatidosis. II. Intense plasmacellular infiltration in the paracortex of draining lymph nodes

Male C57L/J mice were infected subcutaneously in the left flank with 10 cysts of Echinococcus multilocularis. The draining and contralateral nodes were excised at weekly intervals, weighed, and examined histologically. Lymphoproliferation occurred in both the follicles and the paracortex (PCA) of the draining lymph nodes at one week postinfection (p.i.). Disorganization in the PCA of the draining nodes, was characterized by replacement of lymphocytes by plasma cells and the flattening of the endothelial cells lining the postcapillary venules. This began at three weeks p.i. and was completed by 12 weeks p.i. No comparable alterations occurred in the contralateral nodes during this period, but at 22 weeks p.i. these nodes were disorganized and histologically identical to the draining nodes. The growth and histogenesis of the subcutaneous alveolar cysts correlated with the expansion and disorganization of the PCA. The regulation of subcutaneous murine alveolar hydatidosis is discussed with reference to immune-deviation which is brought about by the antigenic load and plasmacellular infiltration in the draining lymph nodes.

[Immune defect syndrome in Crohn's disease (author's transl)]

In 20 patients suffering for several years from serious chronic relapsing Crohn's disease the following immunological tests were carried out: (1) in-vitro stimulation of blood lymphocytes by PHA-P, (2) identification of T and B cells by formation of spontaneous rosettes and complement receptor rosettes, (3) effect of Crohn's serum on mixed lymphocyte reaction (MLR) of normal allogeneic lymphocytes, (4) in-vitro phagocytosis and intracellular killing of E. coli by polymorphonuclear granulocytes. The results indicate an immune defect of lymphocyte function and the effect of humoral factor(s) on T cell mediated immune reactions: (1) Lymphocyte stimulation by PHA-P was reduced significantly in Crohn's disease. In PHA-P dose response, maximal stimulation has shown a decrease and a shift to higher doses. (2) An increase in the absolute number of B cells caused a decrease in the mean percentage of T cells. The absolute number of T cells did not differ significantly from those of the controls. (3) Crohn's serum has shown an inhibitory effect in MLR of normal lymphocytes. (4) No impairment of phagocytosis or intracellular killing by polymorphonuclear granulocytes has been observed. The results suggest a symptomatic immune defect syndrome in a wasting disease. There is no evidence of a primary immune defect in Crohn's disease.

Effect of immunoglobulin G on membrane-bound enzyme activity of sarcoma 180 cells

Changes in the activity of membrane bound ATPase of Sarcoma 180 cells caused by immunoglobulin G (IgG) of anti-Sarcoma 180 was investigated in relation to the incorporation of amino acid by the cells. Enzymatic activity of ATPase was increased up to 160% of the original activity upon incubation of the cell with IgG. Kinetic studies showed that IgG did not change the affinity of this enzyme for the substrate, but exerted influence upon catalytic efficiency of the enzyme. The rate of incorporation of leucine into Sarcoma 180 cells was also affected by IgG, as observed in the effect of IgG on the enzymatic reaction of the cells.

Separation and characterization of anti-benzylpenicilloyl (BPO) antibodies. II. Immunological properties of different IgG fractions

Affinity chromatography and subsequent ion-exchange chromatography of pooled anti-benzylpenicilloyl (anti-BPO) hyperimmune sera separated 5 different anti-BPO IgG fractions as described in the preceding paper. These fractions were tested for activities in passive hemagglutination (PHA), passive immune hemolysis (PIH), antibody-dependent cellular cytotoxicity (ADCC) and influence on IgM-induced hemolysis. It was found that anti-BPO IgG fractions with low avidity (dissociation constant K = 4.4--6.7 X 10(-8) moles/l) were poorly active in PHA and ADCC and had no blocking activity in IgM hemolysis. Among the highly avid antibodies (K = 0.7--3.4 X 10(-8) mole/l) no correlations were found between avidity and activities in the immunological tests. The results presented demonstrate that ion-exchange chromatography allows the separation of blocking and lytic antibodies as shown by their influence on IgM-induced complement-dependent lysis of lightly hapten-coated sheep erythrocytes.

[Limits and possibilities of neoplasm immunotherapy]

Immunological treatment of malignant human tumors has so far met with little success. Based on methods and insights obtained by investigation of corresponding animal models, this article attempts to elucidate the reasons for this failure and to suggest ways and means to improve immunotherapeutic approaches to human neoplasms.

Immunotherapy in the treatment of cancer

This article is a review of immunotherapy in the treatment of cancer incorporating the history of immunotherapy in the nineteenth and twentieth centuries, assessment of the techniques currently in use and of possible future developments. Although immunotherapy is not established as a therapeutic technique, evidence suggests that the immune response does influence the development of neoplastic cells. A better understanding of the immune response and its control may lead to the production of efficacious immunological treatment of certain cancers.

Natural anti-tumor serum reactivity in BALB/c mice. I. Characterization and interference with tumor growth

A natural cytotoxic reactivity directed against syngeneic or allogeneic tumor cells was demonstrated in serum of BALB/c mice by an in vitro cytotoxicity test using rabbit serum as the source of complement. The reactivity, studied on syngeneic fibrosarcoma cells, was found to be minimal in mice less than 10 weeks old and to increase progressively with age. T-deprivation determined an increase of reactivity in young mice to levels reached spontaneously only by the serum of 40-week-old mice. The BALB/c serum also revealed natural anti-thymus antibodies. Non-identity between anti-tumor and anti-thymus antibodies was demonstrated by direct cytotoxicity and absorption tests. An inoculum of syngeneic fibrosarcoma cells increased the level of anti-tumor serum reactivity in both normal and T-deprived young mice. The natural anti-tumor cytotoxicity revelaed in vitro seemed to exert a specific in vivo protection as suggested by the indirect correlation found between the level of the natural anti-tumor reactivity and the grwoth of a transplanted fibrosarcoma.